Sequential monitoring of response-adaptive randomized clinical trials by Zhu, Hongjian & Hu, Feifang
ar
X
iv
:1
01
0.
39
01
v1
  [
ma
th.
ST
]  
19
 O
ct 
20
10
The Annals of Statistics
2010, Vol. 38, No. 4, 2218–2241
DOI: 10.1214/10-AOS796
c© Institute of Mathematical Statistics, 2010
SEQUENTIAL MONITORING OF RESPONSE-ADAPTIVE
RANDOMIZED CLINICAL TRIALS
By Hongjian Zhu and Feifang Hu1
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Clinical trials are complex and usually involve multiple objec-
tives such as controlling type I error rate, increasing power to de-
tect treatment difference, assigning more patients to better treat-
ment, and more. In literature, both response-adaptive randomization
(RAR) procedures (by changing randomization procedure sequen-
tially) and sequential monitoring (by changing analysis procedure
sequentially) have been proposed to achieve these objectives to some
degree. In this paper, we propose to sequentially monitor response-
adaptive randomized clinical trial and study it’s properties. We prove
that the sequential test statistics of the new procedure converge to
a Brownian motion in distribution. Further, we show that the se-
quential test statistics asymptotically satisfy the canonical joint dis-
tribution defined in Jennison and Turnbull (2000). Therefore, type I
error and other objectives can be achieved theoretically by selecting
appropriate boundaries. These results open a door to sequentially
monitor response-adaptive randomized clinical trials in practice. We
can also observe from the simulation studies that, the proposed pro-
cedure brings together the advantages of both techniques, in deal-
ing with power, total sample size and total failure numbers, while
keeps the type I error. In addition, we illustrate the characteristics of
the proposed procedure by redesigning a well-known clinical trial of
maternal-infant HIV transmission.
1. Introduction. Clinical trials usually involve multiple competing ob-
jectives such as maximizing the power of detecting clinical difference among
treatments, minimizing total sample size and protecting more people from
possibly inferior treatments. To achieve these objectives, two different tech-
niques have been proposed in literature: (i) the analysis approach—by ana-
lyzing the observed data sequentially [sequential monitoring, Jennison and
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Turnbull (2000)], and (ii) the design approach—by changing the allocation
probability sequentially [response-adaptive randomization, Hu and Rosen-
berger (2006)]. In this paper, we discuss how to combine the two procedures
in one clinical trial in order to utilize both of their advantages.
In experiments where data accumulates sequentially, it is natural to con-
duct a sequential analysis. Sequential techniques originated from a method-
ology of long history based on Brownian motion. Wald’s classic work about
the sequential probability ratio test (SPRT) [Wald (1947)] led to the appli-
cation of sequential analysis in numerous fields of statistics. Armitage (1957,
1975) introduced sequential methods to clinical studies, which required mon-
itoring results on a patient-by-patient basis. Pocock (1977) proposed sequen-
tial monitoring of clinical trials based on a group basis. Since then, many
authors have done important work on group sequential studies. These work
are summarized in Jennison and Turnbull (2000) and Proschan, Lan and
Wittes (2006).
The main advantages of sequential monitoring were listed in Jennison
and Turnbull (2000). First, it is ethical to monitor clinical trials sequen-
tially because we could ensure that patients are not exposed to dangerous
treatments and we could stop trials as soon as possible if needed. Second,
administratively one needs to ensure that the protocol is not violated and
the assumption, which the clinical trial is based on, is correct and valid.
Third, sequential monitoring can decrease sample size and cost. With all
the above advantages, sequential monitoring has now become a standard
technique in conducting clinical trials.
The idea of response-adaptive randomization (RAR) can be traced back
to Thompson (1933) and Robbins (1952). The play-the-winner rule [Zelen
(1969)] and the randomized play-the-winner rule [Wei and Durham (1978)]
were proposed to reduce number of patients in the inferior treatments. Hu
and Rosenberger (2003) proved theoretically that adaptive randomization
can be used to increase statistical efficiency in some clinical trials. In lit-
erature, many papers showed its efficient and ethical advantages over fixed
designs [Hu and Rosenberger (2006)]. With modern technology and high ca-
pability of collecting data, it becomes easier and easier to implement adap-
tive designs in sequential experiments. Some clinical trials have already im-
plemented the response-adaptive designs [Rout et al. (1993), Tamura et al.
(1994), Andersen (1996), etc.].
Bayesian adaptive designs have also been proposed and studied in liter-
ature. Berry (2005) provided some comprehensive introduction of Bayesian
designs in clinical trials. Recently, Cheng and Shen (2005) proposed to se-
quentially monitor a Bayesian adaptive design using decision-theoretic ap-
proaches and allowing the maximum sample size to be sequentially adjusted
by the observed data. Lewis, Lipsky and Berry (2007) proposed a Bayesian
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decision-theoretic group sequential design for a disease with two possible out-
comes based on a quadratic loss function. Wathen and Thall (2008) studied
Bayesian adaptive model selection for optimizing group sequential clinical
trials. In this paper, we focus on sequential monitoring of response-adaptive
randomized clinical trials.
Traditionally, sequential monitoring deals with fixed designs (usually with
equal allocation). No systematic study is available about sequential monitor-
ing a sequential experiment using response-adaptive randomization, except
a simulation study by Coad and Rosenberger (1999). They found that the
expected number of treatment failures can be further reduced by combining
the triangular test with the randomized play-the-winner rule. In this pa-
per, we will study both theoretical properties and finite sample properties
of combining sequential monitoring with response-adaptive randomization.
Sequential monitoring procedures use responses to stop or continue a clini-
cal trial. Response-adaptive randomization procedures sequentially estimate
the parameters and update the allocation probability of the next patient. To
monitor a response-adaptive randomized clinical trial sequentially, one needs
to study the two sequential procedures simultaneously. This is conceptually
difficult because: (1) the number of patients assigned to each treatment is
a random variable at each time point; (2) both the treatment assignments
(probabilities) and the estimators of parameters (test statistics) depend on
the responses at each time point. These problems arise from the sequen-
tial updating of estimators of the parameters and the allocation probability
function, which leads to difficulties in finding the joint distribution of se-
quential test statistics. We overcome above difficulties by (i) approximating
these different processes by martingale processes at each time point simulta-
neously; (ii) then using continuous Gaussian approximation to study these
martingale processes simultaneously.
In this paper, we discuss sequential monitoring of doubly adaptive biased
coin design proposed by Hu and Zhang (2004) for comparing two treat-
ments. Under widely satisfied conditions, we show that the sequential test
statistics converge to (i) a standard Brownian motion in distribution under
null hypothesis; and (ii) a drifted Brownian motion in distribution under
alternative hypothesis. For a standard Brownian motion, the critical value
for fixed type I error rate has been well studied in literature. Therefore, the
problem of controlling type I error is theoretically solved. Further, we show
that the sequential test statistics satisfy the canonical joint distribution de-
fined in Jennison and Turnbull (2000) asymptotically. Hence, one can apply
the group sequential methods in the book to response-adaptive randomized
clinical trials.
Simulation results support our theoretical founds in terms of type I er-
ror and display that sequential monitoring of response-adaptive randomiza-
tion procedure could increase power and decrease total failure number. Also
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compared to complete randomization, sequential monitoring of response-
adaptive randomization procedure could stop earlier, and thus reduce the
actual sample size. In other words, the proposed procedure achieves the
goals of both RAR and sequential monitoring. We also redesign an exper-
iment evaluating the effect of zidovudine treatment in reducing the risk of
maternal-infant HIV transmission performed by Connor et al. (1994). The
proposed procedure can be used to decrease the number of HIV infected
people and increase the power comparing to the complete randomization.
In Section 2, we introduce the notation, describe the framework and state
the main theorem. In Sections 3 and 4, we use both generated data and real
data to compare the proposed procedure with other randomization proce-
dures. Conclusions are in Section 5 and technical proofs are given in the
Appendix.
2. Sequential monitoring of response-adaptive randomization procedures.
2.1. Notation and framework. We first describe the framework for the
randomized adaptive designs. In this article, we consider clinical trials with
two treatments 1 and 2. Let Ti = (Ti,1, Ti,2) = (1,0), i = 1, . . . , n, if the
ith patient is assigned to treatment 1, and (0,1) otherwise, where n is
the sample size. N(n) = (N1(n),N2(n)), where Nj(n) =
∑n
i=1 Tij , j = 1,2,
is the number of patients in treatment j. Let X = (X1, . . . ,Xn)
′, where
Xi = (Xi1,Xi2), i = 1, . . . , n, is a random matrix of responses variable and
Xij , j = 1,2, are d-dimensional random vectors. Here, only one element of
Xi, say Xij , can be observed if the ith patient is assigned to treatment j.
We assume that X1, . . . ,Xn are independent and identical distributed with
unknown parameter (θ1,θ2), where θj is the corresponding dj -dimensional
parameter vector (θj1, . . . , θjdj) of treatment j (j = 1,2). To simplify the no-
tation, we assume that the parameter vectors of both treatments have the
same dimension (d1 = d2 = d). Without loss of generality, we also assume
that θj =E(Xij). Otherwise, we can transform X and treat the transforma-
tion as responses to make the former equation hold if such transformation
exists. Such transformation usually exists asymptotically. See Gwise, Hu and
Hu (2008) and Hu and Zhang (2004) for further discussion.
Let [nt] denote the largest integer that is smaller than or equal to nt for t ∈
[0,1]. Then N([nt]) = (N1([nt]),N2([nt])) and Nj([nt]) =
∑[nt]
i=1 Tij , j = 1,2.
Note that t=N/n when N is the number of patients who have already been
enrolled. We introduce the so-called information time t in order to formulate
this problem into the Skorohod topology [Ethier and Kurts (1986)]. After
N = [nt] patients have been assigned and the responses observed, we use
the modified sample means θˆ[nt] = (θˆ[nt],1, θˆ[nt],2) to estimate the parameter
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θ = (θ1,θ2), that is,
θˆ[nt],1 =
∑[nt]
i=1 Ti,1Xi1 + θ0,1
N1([nt]) + 1
and θˆ[nt],2 =
∑[nt]
i=1 Ti,2Xi2 + θ0,2
N2([nt]) + 1
.(2.1)
Here, we add 1 in the denominator to prevent discontinuity, and add θ0,j ,
say 0.5, to estimate θj when no patient has been assigned to the treatment
j, j = 1,2.
Let ρ= (ρ1, ρ2) be the target allocation proportion. Usually ρ is obtained
based on some optimal criteria and depends on unknown parameter θ. The
selection of ρ= ρ(θ) has been studied by Hayre (1979), Jennison and Turn-
bull (2000) and Tymofyeyev, Rosenberger and Hu (2007). In practice, the
parameters are unknown. Therefore, we have to first estimate them accord-
ing to previous treatment assignments and responses so that we can target
the allocation proportion. We consider a general family of doubly adaptive
biased coin design (DBCD) [Eisele and Woodroofe (1995)] here.
Doubly adaptive biased coin design: (i) assign the first 2n0 patients to
treatment 1 and 2 by some restricted randomization procedures [permuted
block or truncated binomial randomization, see Rosenberger and Lachin
(2002)]; (ii) when the lth (l > 2n0) patient arrives and all the responses
on the previous l − 1 patients are available, we compute θˆl−1 and ρˆl−1 =
ρ(θˆl−1); (iii) then assign the lth patient to treatment 1 with probability
g(N1(l− 1)/(l− 1), ρ1(θˆl−1)),
where g(s, r) : [0,1]× [0,1]→ [0,1] is the allocation function. Hu and Zhang
(2004) proposed (γ ≥ 0):
g(γ)(0, r) = 1,
g(γ)(1, r) = 0,(2.2)
g(γ)(s, r) =
r(r/s)γ
r(r/s)γ + (1− r)((1− r)/(1− s))γ .
The design has drawn much attention since it was proposed and its advan-
tages and properties can be found in Hu and Rosenberger (2003), Rosen-
berger and Hu (2004) and Tymofyeyev, Rosenberger and Hu (2007).
To compare two treatments in clinical trials, one consider a general hy-
pothesis test:
H0 :h(θ1) = h(θ2) versus H1 :h(θ1) 6= h(θ2),
where h is a ℜd→ℜ function of parameters. In this paper, we assume h(θj)
is continuous and twice differentiable in a small neighborhood of θj, j = 1,2.
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If one would like to test the above hypothesis at time point t ∈ (0,1], it is
natural to construct the test statistic as
Zt
(
N([nt])
[nt]
, θˆ([nt])
)
=
h(θˆ1([nt]))− h(θˆ2([nt]))√
V̂ar(h(θˆ1([nt]))) + V̂ar(h(θˆ2([nt])))
.(2.3)
Here, V̂ar(h(θˆ1([nt]))) and V̂ar(h(θˆ2([nt]))) are some consistent estimators
of the variances of h(θˆ1([nt])) and h(θˆ2([nt])), respectively. There is no co-
variance term on the denominator since the two terms on the numerator are
asymptotically independent [Hu, Rosenberger and Zhang (2006)]. Without
loss of generality, we also assume that for some functions v1 and v2
[nt]V̂ar(h(θˆj([nt]))) = vj
(
N([nt])
[nt]
, θˆ([nt])
)
(1 + o(1)) a.s. j = 1,2.
It is easy to see that both vj(y,z) and Zt(y,z) are ℜ2+2d→ℜ function, where
y is a two-dimensional vector and z is a 2d-dimensional vector. Examples of
using this formulation are discussed in Section 2.3.
2.2. Main results. Based on the notation in Section 2.1, we observe the
random processes (T1, . . . ,T[nt]), (X1, . . . ,X[nt]), N([nt]), θˆ[nt], ρ(θˆ[nt]) and
Zt at time point t. When a response-adaptive randomization procedure is
used, these random processes have the following characteristics different
from those in fixed designs:
(1) The allocation (N([nt])) at any time t is a random vector instead of a
constant in fixed designs.
(2) The allocation (N([nt])) and (T1, . . . ,T[nt]) are not independent with
the responses (X1, . . . ,X[nt]) and the parameter estimator vector θˆ[nt].
(3) The elements θˆ1[nt] and θˆ2[nt] depend on each other at any given time
t ∈ (0,1].
These differences directly lead to difficulties in deriving the joint distribu-
tions of sequential testing statistics.
To sequentially monitor a clinical trial, we need to figure out how to
control the type I error. The answer to this question relies on the derivation
of the asymptotical joint distribution of the sequential statistics and right
choices of the boundaries. Before we give the main theorem, we need the
following conditions for the response X, target allocation ρ(θ), allocation
function g and the function vj(y,z), j = 1,2.
(A1) For some ε > 0, E‖X1‖2+ε <∞;
(A2) g(s, r) is jointly continuous and twice differentiable at (ρ1, ρ1);
(A3) g(r, r) = r for all r ∈ (0,1) and g(s, r) is strictly decreasing in s and
strictly increasing in r on (0,1)× (0,1);
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(A4) ρ(z) is a continuous function and twice continuously differentiable
in a small neighborhood of θ;
(A5) vj(y,z) is jointly continuous and twice differentiable in a small neigh-
borhood of (ρ,θ);
(A6) Zt(y,z) is a continuous function and it is twice continuously differ-
entiable in a small neighborhood of vector (ρ,θ).
Remark 2.1. All the conditions are widely satisfied. An example of a
design which satisfies these conditions is DBCD in Hu and Zhang (2004).
Condition (A1) is used to ensure the consistency of the procedure and
asymptotic normality of the allocation proportions. Condition (A3) forces
the actual allocation proportion to approach the theoretically targeted one.
Conditions (A4), (A5) and (A6) are satisfied in all the examples in Chapter
5 of Hu and Rosenberger (2006).
Theorem 2.1. Let Bt =
√
tZt in the space D[0,1] with Skorohod topology.
Assume conditions (A1)–(A6) are satisfied. Then we have the following two
results:
(i) Under H0, Bt is asymptotically a standard Brownian motion in dis-
tribution.
(ii) Under H1, Bt−
√
nµt is asymptotically a standard Brownian motion
in distribution, where
µ=
(h(θ1)− h(θ2))√
v1(ρ,θ) + v2(ρ,θ)
.
Based on Theorem 2.1, we can obtain the asymptotical distribution of the
sequence of test statistics {Zt1 , . . . ,ZtK}, where 0 ≤ t1 ≤ t2 ≤ · · · ≤ tK ≤ 1.
Because Zti = (
√
ti)
−1Bti , we have asymptotically:
(i) {Zt1 , . . . ,ZtK} is multivariate normal;
(ii) EZti = µ
√
nti; and
(iii) Cov(Zti ,Ztj ) =
√
[nti]/[ntj ],0≤ ti ≤ tj ≤ 1.
Therefore, the sequence of test statistics {Zt1 , . . . ,ZtK} has the asymp-
totical canonical joint distribution defined in Jennison and Turnbull (2000).
Remark 2.2. Based on the canonical joint distribution of the sequence
of test statistics {Zt1 , . . . ,ZtK}, we can see that the doubly adaptive biased
coin design has a simple form of information time, which is just the pro-
portion of the sample size enrolled. This is because the DBCD consistently
allocates same proportion of patients to different treatments from the be-
ginning to the end asymptotically. We conjecture that this simple form of
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information time is true for most response-adaptive randomization proce-
dures.
Based on Theorem 2.1, we can easily choose the correct critical values
for the asymptotic Brownian process, so that the inflation of the type I er-
ror will be avoided. Moreover, we can also make use of all the well-known
properties of Brownian process to do further analysis on the process of
sequentially monitoring a response-adaptive randomization procedure. Be-
cause {Zt1 , . . . ,ZtK} satisfies the canonical joint distribution asymptotically,
we can apply the sequential techniques in Chapters 2, 3, 4, 5, 6, 7 of Jenni-
son and Turnbull (2000) to response-adaptive randomized clinical trials. We
may also apply different types of spending functions to monitor a response-
adaptive randomized clinical trial sequentially. Here, we will use α spending
functions proposed by Lan and DeMets (1983).
Any increasing function α(t) defined on [0,1] with α(0) = 0 and α(1) = α
is called a α spending function. We spend α(ti)−α(ti−1) of the total type I
error rate at time point ti, so that α(ti) has been spent after this point. For
time ti, i= 1,2, . . . , we can sequentially obtain the boundaries. This method
does not require the predetermined number of looks and equally spaced
looks. We can perform the interim monitor anytime during the trial. Such
a procedure is usually preferred by Data and Safety Monitoring Boards
(DSMB). Proschan, Lan and Wittes (2006) provided three special spend-
ing functions. The first one approximates the O’Brien–Fleming boundaries
[O’Brien and Fleming (1979)]
α1(t) = 2{1−Φ(zα/2/t1/2)}.
The second one is the linear spending function:
α2(t) = αt.
The third one approximates the Pocock boundaries [Pocock (1982)]:
α3(t) = α ln{1 + (e− 1)t}.
The O’Brien–Fleming-like function spends little of the type I error at early
looks. Consequently, the boundary for the last look is very close to what it
would have been without sequential monitoring. Conversely, the Pocock-like
function rejects the null hypothesis easier with smaller boundaries for early
looks and then has to use a reasonably large critical value at the end to
keep the type I error. The linear function is between these two. Therefore,
the three functions above represent three typical types of spending func-
tion. Finally, it is worth mentioning that these three spending functions are
corresponding to the process Zt.
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2.3. Examples. Here, we use two examples to illustrate how to sequen-
tially monitor the response-adaptive randomization procedures based on
Theorem 2.1.
Example 1 (Continuous responses from normal populations). Suppose
the responses of the two treatments are from two normal distributions Yi1 ∼
N(µ1, σ
2
1) and Yi2 ∼N(µ2, σ22), i= 1, . . . , n. We would like to compare µ1 and
µ2. In this case, θ1 = (µ1, σ
2
1 + µ
2
1), θ2 = (µ2, σ
2
2 + µ
2
2), Xij = (Yij, Y
2
ij) and
h(θj) = θj1 = µj, j = 1,2. Then the hypotheses are
H0 :µ1 = µ2 versus H1 :µ1 6= µ2.
Let target allocation proportion be the Neyman allocation [Jennison and
Turnbull (2000)] with
ρ1 =
σ1
σ1 + σ2
and ρ2 = 1− ρ1 = σ2
σ1 + σ2
.(2.4)
We can use other target allocation proportions, for example, the optimal
allocation proportion [Zhang and Rosenberger (2006)] and the DA-optimal
allocation proportion [Gwise, Hu and Hu (2008)]. The sequential statistics
Zt(y,z) is a function from ℜ6 to ℜ:
Zt(y,z) =
z11 − z21√
(z12 − z211)/([nt]y1) + (z22 − z221)/([nt]y2)
,
where y =N([nt])/[nt] and z = θˆ = (θˆ11([nt]), θˆ12([nt]), θˆ21([nt]), θˆ22([nt])).
It is easy to see that h(θˆ1([nt])) = µˆ1([nt]) and h(θˆ2([nt])) = µˆ2([nt]). Also
the natural variance estimators are
V̂ar(h(θˆ1([nt]))) =
σˆ21([nt])
N1([nt])
and V̂ar(h(θˆ2([nt]))) =
σˆ22([nt])
N2([nt])
,
where σˆ21([nt]) and σˆ
2
2([nt]) are the usual unbiased estimators of σ
2
1 and σ
2
2
based on the first [nt] responses (N1([nt]) from treatment 1 and N2([nt])
from treatment 2), respectively. Therefore,
v1(ρ,θ) =
σ21
ρ1
and v2(ρ,θ) =
σ22
ρ2
.
The test statistic is then
Zt =
µˆ1([nt])− µˆ2([nt])√
σˆ21([nt])/N1([nt]) + σˆ
2
2([nt])/N2([nt])
.(2.5)
Then based on Theorem 2.1, the joint distribution of Bt =
√
tZt is asymp-
totically a standard Brownian process under H0. Under H1, Bt −
√
nµt is
asymptotically a standard Brownian motion in distribution, where
µ=
µ1− µ2√
σ21/ρ1 + σ
2
2/(1− ρ1)
.
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Example 2 (Binary responses). Assume Yi1 ∼ Bin(1, p1) and Yi2 ∼Bin(1,
p2), i = 1, . . . , n, and we would like to compare p1 and p2. In this case,
θ1 = (p1), θ2 = (p2), Xij = (Yij) and h(θj) = θj1, j = 1,2. The hypotheses
are
H0 :p1 = p2 versus H1 :p1 6= p2.
Three common target allocations are: (i) Neyman allocation,
ρ1 =
√
p1(1− p1)√
p1(1− p1) +
√
p2(1− p2)
and
(2.6)
ρ2 =
√
p2(1− p2)√
p1(1− p1) +
√
p2(1− p2)
;
(ii) optimal allocation proposed by Rosenberger et al. (2001),
ρ1 =
√
p1√
p1+
√
p2
and ρ2 =
√
p2√
p1 +
√
p2
;(2.7)
(iii) Urn allocation [Wei and Durham (1978)],
ρ1 =
q2
q1 + q2
and ρ2 =
q1
q1 + q2
.(2.8)
Neyman allocation is a commonly discussed allocation which is related
to the efficiency issue in the field of response-adaptive randomization proce-
dures. We studied sequential monitoring of response-adaptive designs with
Neyman allocation in order to show that our proposed procedure is able to
achieve various objects.
In this case, Zt(y,z) is a function from ℜ4 to ℜ:
Zt(y,z) =
z11 − z21√
z11(1− z11)/([nt]y1) + z21(1− z21)/([nt]y2)
,
where y = (N1([nt])/[nt],N2([nt])/[nt]), z = (θˆ11([nt]), θˆ21([nt])), h(θˆ1([n×
t])) = pˆ1([nt]) and h(θˆ2([nt])) = pˆ2([nt]). The corresponding variance esti-
mators are
V̂ar(h(θˆ1([nt]))) =
pˆ1([nt])(1− pˆ1([nt]))
N1([nt])
and
V̂ar(h(θˆ2([nt]))) =
pˆ2([nt])(1− pˆ2([nt]))
N2([nt])
.
Therefore,
v1(ρ,θ) =
p1(1− p1)
ρ1
and v2(ρ,θ) =
p2(1− p2)
ρ2
.
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The test statistic is
Zt = (pˆ1([nt])− pˆ2([nt]))
(2.9)
×
(√
pˆ1([nt])
1− pˆ1([nt])
N1([nt])
+ pˆ2([nt])
1− pˆ2([nt])
N2([nt])
)
−1
.
Then Bt =
√
tZt converges to a standard Brownian process in distribution
under H0. Under H1, Bt −
√
nµt is asymptotically a standard Brownian
motion in distribution, where
µ=
p1− p2√
p1(1− p1)/ρ1 + p2(1− p2)/(1− ρ1)
.
Theorem 2.1 can be applied to different situations such as the examples
considered in Chapter 5 of Hu and Rosenberger (2006). In Examples 1 and
2, now assume we would like to look at the process at three points: t1 = 0.2,
t2 = 0.5 and t3 = 1. Then we can use the corresponding critical values from
the three spending functions [Proschan, Lan and Wittes (2006)] in the last
subsection for Zt to keep the overall type I error 0.05: O’Brien–Fleming-like
boundaries (4.877, 2.963, 1.969), linear boundaries (2.576, 2.377, 2.141) and
Pocock-like boundaries (2.438, 2.333, 2.225).
3. Simulation study. In Section 2, we obtained the asymptotical distri-
bution of the test statistic Zt. In this section, we will use the two examples
in Section 2 to study the finite sample properties of the proposed procedure.
In Examples 1 and 2, we use the doubly adaptive biased coin design with
Hu and Zhang’s allocation function in (2.2) and γ = 2 is used. In Tables
1–5, we use the same total sample size 500. The first 50 patients (n0 =
25) are randomly assigned to treatments 1 and 2 by using permuted block
randomization. Then, for the lth (l > 50) patient, the unknown parameters
are estimated by using (2.1) based on the first l − 1 responses with θ0,1 =
θ0,2 = 0.5. For normal responses in Example 1, we estimate σ
2
1 and σ
2
2 by
using the standard unbiased estimators based on the first l− 1 responses.
For simplicity, we look at the test at three time points [n1 = 100 (t1 = 0.2),
n2 = 250 (t2 = 0.5) and n = 500 (t3 = 1)]. Then the three sets of spending
function boundaries in Section 2.3 are used to ensure α = 0.05. For each
spending function, the first row in the table is for DBCD and the second
row is for complete randomization (denoted as CR in the tables). All the
simulations are based on 5000 replications.
In Table 1, we simulate Example 1 with two normal responses N(1,1)
and N(1,2) by using the Neyman allocation (2.4). We find that the type I
error of sequentially monitoring the response-adaptive randomization pro-
cedure and complete randomization are both well kept at the 0.05 level. We
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Table 1
Example 1 with Neyman allocation, µ1 = µ2 = 1, σ1 = 1, σ2 = 2
Critical values Randomization Type I error ρˆ1 (s.e.)
B–F-like DBCD 0.055 0.333 (0.020)
B–F-like CR 0.052 0.500 (0.022)
Linear DBCD 0.048 0.333 (0.020)
Linear CR 0.053 0.500 (0.023)
Pocock-like DBCD 0.051 0.332 (0.020)
Pocock-like CR 0.052 0.500 (0.023)
also report the mean and standard deviation of actual allocation proportion
(ρˆ1) for treatment 1 [N(1,1)]. We find that the mean agrees with Neyman
allocation and the standard deviation is reasonably small for DBCD. This
indicates that the DBCD is able to target the theoretical targeted allocation
proportion very well. In Table 2, we simulate the Example 2 with two binary
responses p1 = p2 = 0.5 and the target allocation is the optimal allocation
(2.7). We obtain the same conclusion as Table 1. We have also done simula-
tions for some other cases, and similar results are obtained. These numerical
results indicate that sequential monitoring of the response-adaptive random-
Table 2
Example 2 with optimal allocation, p1 = p2 = 0.5
Critical values Randomization Type I error ρˆ1 (s.e.)
B–F-like DBCD 0.051 0.500 (0.016)
B–F-like CR 0.046 0.500 (0.023)
Linear DBCD 0.055 0.500 (0.019)
Linear CR 0.061 0.500 (0.023)
Pocock-like DBCD 0.056 0.500 (0.019)
Pocock-like CR 0.050 0.500 (0.022)
Table 3
Example 1 with Neyman allocation, µ1 = 1, µ2 = 1.4, σ1 = 1, σ2 = 2
Critical values Randomization Power ρˆ1 (s.e.) N1 N2 N3
B–F-like DBCD 0.847 0.333 (0.021) 2 1013 3222
B–F-like CR 0.807 0.500 (0.024) 1 842 3193
Linear DBCD 0.812 0.332 (0.027) 594 1429 2035
Linear CR 0.765 0.500 (0.028) 477 1380 1970
Pocock-like DBCD 0.792 0.332 (0.028) 741 1443 1774
Pocock-like CR 0.738 0.500 (0.028) 544 1309 1835
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ization will not inflate the type I error with the appropriate boundaries based
on Theorem 2.1.
Next, we show other advantages of the sequential monitoring of the response-
adaptive randomization procedure. In Table 3, we simulate Example 1 with
two normal responses N(1,1) and N(1.4,2) using Neyman allocation (2.4)
as the target allocation that maximizes the power. The power of the sequen-
tial monitoring of the response-adaptive randomization procedure is about
5%–8% higher than sequentially monitoring the complete randomization.
Ni in the table is the number of rejections at the ith look. Rejection at
the first two looks means stopping the trial earlier. DBCD with sequential
monitoring obviously stops the trial earlier than complete randomization.
In Table 4, we simulate Example 2 with two binary responses p1 = 0.5
and p2 = 0.625 using the urn allocation (2.8) as the target allocation that
assigns more people to the better treatment. If we reject the null hypothesis
at the first two looks, we assign all the remaining patients to the estimated
better treatment and count the total failure number. We do this only for the
comparison in the simulation study. In a real clinical trial, we stop the trial if
the null hypothesis is rejected at an interim look. From the mean total failure
number, the DBCD with sequential monitoring has lower failure numbers
Table 4
Example 2 with urn allocation, p1 = 0.5, p2 = 0.625
Critical values Randomization Power ρˆ1 (s.e.) N1 N2 N3 Total failures (s.e.)
B–F-like DBCD 0.811 0.426 (0.033) 4 839 3214 211 (13)
B–F-like CR 0.811 0.500 (0.024) 1 839 3215 217 (13)
Linear DBCD 0.762 0.421 (0.041) 503 1396 1912 206 (14)
Linear CR 0.767 0.500 (0.029) 521 1300 2016 212 (14)
Pocock-like DBCD 0.749 0.421 (0.042) 609 1325 1809 205 (14)
Pocock-like CR 0.738 0.501 (0.029) 603 1312 1773 211 (15)
Table 5
Example 2 with optimal allocation, p1 = 0.5, p2 = 0.625
Critical values Randomization Power ρˆ1 (s.e.) N1 N2 N3 Total failures (s.e.)
B–F-like DBCD 0.810 0.471 (0.017) 4 863 3185 214 (12)
B–F-like CR 0.805 0.501 (0.024) 4 795 3229 218 (13)
Linear DBCD 0.768 0.468 (0.022) 520 1354 1964 210 (14)
Linear CR 0.762 0.500 (0.029) 474 1367 1971 214 (14)
Pocock-like DBCD 0.754 0.469 (0.023) 673 1309 1787 210 (14)
Pocock-like CR 0.749 0.500 (0.03) 602 1351 1793 213 (15)
1.96 DBCD 0.805 0.472 (0.015) NA NA NA 217 (11)
1.96 CR 0.802 0.500 (0.022) NA NA NA 221 (11)
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Table 6
Re-designed the HIV trial with full sample size
Target allocation Critical values ρˆ1 (s.e.) Power Total failures (s.e.)
CR linear 0.500 (0.039) 0.999 60.1 (11.1)
CR 1.96 0.501 (0.023) 0.999 80.7 (8.2)
Urn allocation linear 0.751 (0.062) 0.996 52.3 (9.2)
Optimal allocation linear 0.527 (0.021) 0.997 56.4 (10.8)
than complete randomization for each type of spending function. N1, N2,
and N3 show that our methods stop the trial a little earlier and the power
is almost the same.
In Table 5, we simulate Example 2 with two binary responses p1 = 0.5 and
p2 = 0.625 using the optimal allocation (2.7) used to maximize the power
while keeping the total failure number. We deal with the remaining patients
in the same way as in Table 4 if we reject the null hypothesis at the first
two looks. We find that sequential monitoring of the response-adaptive ran-
domization procedure can achieve the aim of optimal allocation. Its power is
larger and its failure number is less than the complete randomization proce-
dure. In this table, we also do the simulation without sequential monitoring.
That is, we only look at the test once at the end of the trial and the criti-
cal value is 1.96 for the nominal significance level 0.05. We report it at the
last two rows. It is obvious that sequential monitoring can reduce the total
failures.
Based on the simulation results, we can see the advantages of sequentially
monitoring response-adaptive randomized clinical trials: (i) controlling type
I error well; (ii) reducing the total number of failures; (iii) increasing power;
and (iv) stopping the trail earlier (reducing total sample size).
4. Re-designing the HIV transmission trial. Maternal-infant transmis-
sion is the primary means by which infants are infected by HIV virus. Con-
nor et al. (1994) reported a trial to evaluate the drug AZT (Zidovudine
treatment) in reducing the risk of maternal-infant HIV transmission. In this
clinical trial, 477 HIV-infected pregnant women were enrolled from April
1991 to December 1993 and assigned to the Zidovudine treatment group
and placebo group with a 50–50 randomization scheme. This experiment
was a randomized, double-blind and placebo-controlled trial. 239 were allo-
cated to the treatment group and 238 to the placebo group. At the end of
the trial, 8.3% of the infant from the treatment group were infected by the
HIV virus, while 25.5% from the placebo group were infected.
In Table 6, we redesign the study by sequential monitoring of both com-
plete randomization (the first two rows in the table) and response-adaptive
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Table 7
Re-designed the HIV trial with sample size n= 245
Target allocation Critical values ρˆ1 (s.e.) Power Total failures (s.e.)
CR B–F-like 0.500 (0.036) 0.947 40.1 (7.0)
CR linear 0.501 (0.042) 0.942 36.6 (7.5)
CR 1.96 0.500 (0.032) 0.958 43.1 (5.8)
Urn allocation B–F-like 0.745 (0.068) 0.920 30.7 (5.9)
Urn allocation linear 0.747 (0.074) 0.885 29.3 (6.1)
Optimal allocation B–F-like 0.528 (0.023) 0.952 36.8 (6.7)
Optimal allocation linear 0.529 (0.025) 0.945 32.8 (7.3)
randomization [DBCD (2.2) with γ = 2] (the last three rows in the table). We
assume the success rate for the treatment group is p1 = 0.917 and that for
the placebo group is p2 = 0.745 (as reported in the original paper). We look
at the test at the three same time points as mentioned in the last section,
n1 = 95 (t1 = 0.2), n2 = 143 (t2 = 0.5) and n= 239 (t3 = 1). The boundary
we use is the linear spending function (2.576, 2.377, 2.141) except the second
row in the table where we do the equal allocation without sequential moni-
toring. We report the actual allocation proportion for the treatment group,
power and the total HIV-infected number. As before, if we reject the null
hypothesis at the first two looks, we will assign all the remaining patients
to the estimated better treatment. We find that the sequential monitoring
technique will decrease the HIV-infected number dramatically from the first
two rows. Response-adaptive randomization technique will also reduce the
HIV-infected number compared to the complete randomization. Sequential
monitoring DBCD while targeting at the urn allocation has the least HIV-
infected number, which agrees with the aim of urn allocation.
In Table 7, we reduce the full sample size to 245 (to achieve power 0.95
for complete randomization) and keep all the other settings unchanged. We
obtain the same conclusion about the HIV-infected number as in Table 6. We
also find that targeting optimal allocation with DBCD has slightly higher
power than targeting equal allocation when sequential monitoring is used.
Targeting urn allocation with DBCD has slightly less power but the HIV-
infected number in this way is the least. Overall, sequential monitoring of the
response-adaptive randomization procedure is better than that of complete
randomization, since it reduces the HIV-infected number and remains good
power.
5. Conclusion remarks. Now sequential monitoring becomes a standard
technique in clinical trials. To apply response-adaptive randomization in
clinical trials, it is important to know how to sequentially monitor adaptive
randomized trials. In this paper, we overcome this hurdle and show the
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advantages of sequential monitoring response-adaptive randomized clinical
trials both theoretically and numerically. We use a Gaussian process in the
Skorohod topology to describe the relationship between the allocation and
parameter estimators. One of the main contributions of this paper is to
show that sequential statistics can be asymptotically approximated by a
Brownian process in distribution under both null and alternative hypotheses.
Further, we find that the sequential test statistics satisfy the canonical joint
distribution asymptotically. Consequently, the results of this paper not only
solve the problem of preserving a preset type I error but may lead to many
area of potential future research.
We have studied how to sequentially monitor a clinical trial based on
doubly adaptive biased coin design proposed by Eisele and Woodroofe (1995)
and Hu and Zhang (2004). Another important family of response-adaptive
randomization procedure is based on urn models, which include randomized
play-the-winner rule [Wei and Durham (1978)], generalized Friedman’s urn
models [Athreya and Karlin (1968), Bai and Hu (2005)], drop-the-loser rule
[Ivanova (2003)], sequential estimation-adjusted urn models [Zhang, Hu and
Cheung (2006)], etc. The technique used in this paper opens a door to study
the properties of sequential monitoring of clinical trials based on these urn
models or the efficient randomized adaptive designs [Hu, Zhang and He
(2009)]. We leave this for future study.
In this paper, we have used α-spending function to calculate the critical
boundaries. Because the sequential test statistics satisfy the canonical joint
distribution asymptotically, we can implement all the sequential techniques
introduced in Jennison and Turnbull (2000) based on this canonical form.
Also we can use the optimal spending functions in Anderson (2007), or the
beta spending functions in DeMets (2006). We also leave the details for
future research.
APPENDIX: PROOFS
First, we introduce some further notation. For a function η(u,w) :ℜL ×
ℜM →ℜ2, we denote the partial derivative matrices as
∇u(η) =
(
∂ηk
∂ui
; i= 1, . . . ,L, k = 1,2
)
L×2
and
∇w(η) =
(
∂ηk
∂wj
; j = 1, . . . ,M,k= 1,2
)
M×2
.
Let H =∇r(g(r, s),1−g(r, s))|(ρ1 ,ρ1) and E =∇s(g(r, s),1−g(r, s))|(ρ1 ,ρ1) be
the partial derivative matrices of the allocation function g. Further, let V =
diag(var(X11)/ρ1,var(X12)/ρ2), Σ3 = (∇(ρ)|θ)′V∇(ρ)|θ , Σ1 = diag(ρ)−ρ′ρ
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and Σ2 = E
′Σ3E. In Hu and Zhang (2004), they studied the asymptotic
properties of N(n), ρˆ(n) and θˆ(n) at the end of the trial. Based on their
results, one can do the corresponding statistical inference after observing all
responses of the clinical trial. To monitor the response-adaptive randomized
trial sequentially, we need to know the theoretical properties of the process
N([nt]) and θˆ([nt]) for any given t ∈ (0,1]. To do this, we start with Lemma
A.1.
Lemma A.1. Let W1t and W2t be two independent standard
two-dimensional Brownian processes. N([nt]), θˆ([nt]), ρ and θ are defined
as in Section 2. Under the conditions of Theorem 2.1, we have
n−1/2([nt])
(
N([nt])
[nt]
− ρ, θˆ([nt])− θ
)
→ (Gt,W2tV 1/2)(A.1)
in distribution in the space D[0,1] with the Skorohod topology, where the Gaus-
sian process
Gt =
∫ t
0
(dW1x)Σ
1/2
1
(
t
x
)H
+
∫ t
0
(dW2x)Σ
1/2
2
[∫ t
x
1
y
(
t
y
)H
dy
]
,(A.2)
which is the solution of the stochastic differential equation
dGt = (dW1t)Σ
1/2
1 +
W2tΣ
1/2
2
t
dt+
Gt
t
H dt with G0 = 0,
and aH is the matrix power function defined as
aH = eH lna =
∞∑
j=0
(lna)j
j!
Hk.
Proof. It is worth noting that the response-adaptive design in The-
orem 2.1 satisfies all the conditions of Hu and Zhang (2004). So all the
results in Hu and Zhang (2004) are valid. We will prove this lemma by using
the weak convergence of the martingale [cf. Theorem 4.1 of Hall and Heyde
(1980)]. To do this, we first approximate the process (N([nt])[nt] −ρ, θˆ([nt])−θ)
by a martingale and then prove the following two facts: (1) Lindeberg con-
dition holds for the approximated martingale process; and (2) the limiting
covariance of n−1/2([nt])(([nt])−1N([nt])− ρ, θˆ([nt]) − θ) agrees with that
of (Gt,W2tV
1/2).
Now, we use the martingale approximation of N(n)− nρ and θˆ(n)− θ
from Hu and Zhang (2004). Let Fm = σ(T1, . . . ,Tm,X1, . . . ,Xm) be the σ-
field generated by the previous m stages. Then under Fm−1, Tm and Xm
are independent, and
E[Tm1|Fm−1] = g
(
N1(m− 1)
m− 1 , ρˆ1(m− 1)
)
.
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LetQn =
∑n
m=1∆Qm, where ∆Qm = (∆Qm,1,∆Qm,2) = (∆Qm,1k,∆Qm,2k;
k = 1, . . . , d) and ∆Qm,jk = Tm,j(Xm,jk − θjk)/ρj , j = 1,2. Then Qn =
O(
√
n log logn) a.s. is a sequence of martingales and we can prove
θˆ(n)− θ = Qn
n
+O
(
log logn
n
)
a.s.(A.3)
Let Mn =
∑n
m=1∆Mm, where ∆Mm = Tm − E[Tm|Fm−1], and Bn,m as
defined in Hu and Zhang (2004), then
N(n)− nρ=
n∑
m=1
∆MmBn,m +
n∑
m=1
∆Qm∇(ρ)
∣∣∣
θ
E
n∑
k=m
1
k
Bn,k + o(n
−1/2−δ/3)
:=Un + o(n
−1/2−δ/3)
almost surely, where Un is a sum of martingale differences.
We can approximate the process N([nt])− [nt]ρ and θˆ([nt])− θ (for any
point t ∈ (0,1]) similarly as N(n)− nρ and θˆ(n)− θ. We obtain
θˆ([nt])− θ = Q[nt]
[nt]
+O
(
log log[nt]
[nt]
)
a.s.(A.4)
and
N([nt])− [nt]ρ
=
[nt]∑
m=1
∆MmB[nt],m+
[nt]∑
m=1
∆Qm∇(ρ)
∣∣∣
θ
E
[nt]∑
k=m
1
k
B[nt],k + o(([nt])
−1/2−δ/3)
:=U[nt] + o(([nt])
−1/2−δ/3)
almost surely.
Hu and Zhang (2004) proved that both martingales Qn and Un satisfy
the Lindberg conditions. Similarly, we can show that both martingales Q[nt]
and U[nt] also satisfy the Lindberg conditions. Now we just have to calculate
the covariance matrix of the martingales Q[nt] and U[nt]. First, based on the
results of Hu and Zhang (2004), we have
ρˆ(n)− ρ=O
(√
log logn
n
)
and n−1N(n)− ρ=O
(√
log logn
n
)
almost surely. Therefore, for any t ∈ (0,1], we have
ρˆ([nt])− ρ=O
(√
log log[nt]
[nt]
)
and
(A.5)
([nt])−1N([nt])− ρ=O
(√
log log[nt]
[nt]
)
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almost surely. Now, we can calculate Var[∆M[nt]|F[nt]−1], Var[∆Q[nt]|F[nt]−1]
and Cov[∆M[nt],∆Q[nt]|F[nt]−1].
First, ∆M[nt] =T[nt] −E[T[nt]|F[nt]−1] is a binary random vector. Based
on conditions (A2), (A3) and (A.5), we have
Var[∆M[nt]|F[nt]−1] = Σ1 + o(1)(A.6)
almost surely. Similarly, we can show
Var[∆Q[nt]|F[nt]−1] = V + o(1)(A.7)
and
Cov[∆M[nt],∆Q[nt]|F[nt]−1] = o(1)(A.8)
almost surely.
Based on results (A.6), (A.7) and (A.8), it follows that for any 0 < s <
t < 1,
Cov[Q[ns],Q[nt]] = Cov
(
[ns]∑
m=1
∆Qm,
[nt]∑
m=1
∆Qm
)
= ns(V + o(1)) = nsV + o(n),
Cov[U[ns],U[nt]] = n∧11 (s, t) + o(n),
Cov[Q[ns],U[nt]] = Cov
[ [ns]∑
m=1
∆Qm,
[nt]∑
m=1
∆MmB[nt],m
+
[nt]∑
m=1
∆Qm∇(ρ)
∣∣∣
θ
E
[nt]∑
k=m
1
k
B[nt],k
]
=Cov
[
[ns]∑
m=1
∆Qm,
[nt]∑
m=1
∆MmB[nt],m
]
+Cov
[ [ns]∑
m=1
∆Qm,
[nt]∑
m=1
∆Qm∇(ρ)
∣∣∣
θ
E
[nt]∑
k=m
1
k
B[nt],k
]
=Cov
[ [ns]∑
m=1
∆Qm,
[nt]∑
m=1
∆Qm∇(ρ)
∣∣∣
θ
E
[nt]∑
k=m
1
k
B[nt],k
]
= (V∇(ρ)|θE + o(1))
[ns]∑
m=1
( [nt]∑
k=m
1
k
B[nt],k
)
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= nV∇(ρ)|
θ
E
∫ s
0
dx
[∫ t
x
t
y
(
t
y
)H
dy
]
+ o(n)
= n∧21 (s, t) + o(n),
and similarly,
Cov[Q[nt],U[ns]] = n∧12 (s) + o(n),
where
∧11(s, t) =
∫ s
0
(
s
x
)H′
Σ1
(
t
x
)H
dx
+
∫ s
0
dx
[∫ s
x
1
y
(
s
y
)H
dy
]
′
Σ2
[∫ t
x
1
y
(
t
y
)H
dy
]
,
∧21(s, t) = V∇(ρ)|θE
∫ s
0
dx
[∫ t
x
t
y
(
t
y
)H
dy
]
,
∧12(s) =
∫ s
0
dx
[∫ s
x
s
y
(
s
y
)H
dy
]
E′∇(ρ)|′
θ
V.
Therefore, the asymptotic covariance function of n−1/2(U[nt],Q[nt]) agrees
with that of (Gt,W2tV
1/2). So by weak convergence of the martingale [cf.
Theorem 4.1 of Hall and Heyde (1980)], we have
n−1/2([nt])
(
N([nt])
[nt]
− ρ, θˆ([nt])− θ
)
→ (Gt,W2tV 1/2)
in distribution in the space D[0,1] with the Skorohod topology. 
Proof of Theorem 2.1. We assume for j = 1,2
[nt]V̂ar(h(θˆj([nt]))) = [nt]vj(N([nt])/[nt], θˆ([nt]))(1 + oP (1))
and
[nt]Var(h(θˆj([nt]))) = [nt]vj(ρ,θ),
where v is a continuous function. We also assume
[nt]vj(N([nt])/[nt], θˆ([nt])) = [nt]vj(ρ,θ) +O
(√
log log[nt]
[nt]
)
a.s.,
which holds for most circumstances, since
N([nt])/[nt] = ρ+O
(√
log log[nt]
[nt]
)
a.s.
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and
θˆ([nt]) = θ+O
(√
log log[nt]
[nt]
)
a.s.
So
[nt]V̂ar(h(θˆj([nt]))) = [nt]Var(h(θˆj([nt]))) +OP
(√
log log[nt]
[nt]
)
.
That is, [nt]V̂ar(h(θˆj([nt]))) converges to [nt]Var(h(θˆj([nt]))), j = 1,2, in
probability. By Slutsky’s theorem, the sequential statistics
Bt
(
N([nt])
[nt]
, θˆ([nt])
)
=
√
t
h(θˆ1([nt]))− h(θˆ2([nt]))√
V̂ar(h(θˆ1([nt]))) + V̂ar(h(θˆ2([nt])))
and
B∗t (θˆ([nt])) =
√
t
h(θˆ1([nt]))− h(θˆ2([nt]))√
Var(h(θˆ1([nt]))) +Var(h(θˆ2([nt])))
have the same distribution asymptotically. So we only need to prove the
sequential statistics B∗t converges to Brownian motion in distribution. Now
h(θˆj)− h(θj) = (θˆj − θj)(∂h(θj)/∂θj)′ + o(‖θˆj − θj‖1+δ)
= (θˆj − θj)(∂h(θj)/∂θj)′ + o(n−1/2−δ/3) a.s., j = 1,2.
It is easy to see that
Var[θˆj([nt])] = Var[θˆj(n)]/t+ o(n
−1) a.s., j = 1,2.
Here, we define
C =
√
Var[h(θˆ1([nt]))] + Var[h(θˆ2([nt]))]
√
Var[h(θˆ1([ns]))] +Var[h(θˆ2([ns]))]
and
D= (∂h(θ1)/∂θ1,−∂h(θ2)/∂θ2).
Then
B∗t (θˆ([nt])) =
√
t
h(θˆ1([nt]))− h(θˆ2([nt]))√
Var(h(θˆ1([nt]))) + Var(h(θˆ2([nt])))
=
√
t
h(θ1)− h(θ2) + (θˆ([nt])− θ)D′ + o(n−1/2−δ/3)√
Var(h(θˆ1([nt]))) +Var(h(θˆ2([nt])))
.
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By the conclusion of Lemma A.1:
n−1/2([nt])(θˆ([nt])− θ)→ (W2tV 1/2)
in distribution in the space D[0,1] with the Skorohod topology. Under H0,
we have
B∗t =
√
t
n1/2([nt])−1W2tV
1/2D′√
Var(h(θˆ1([nt]))) +Var(h(θˆ2([nt])))
+ o(n−δ/3)
almost surely. So the sequential statistics B∗t converges to a Gaussian process
in distribution. In order to prove that B∗t converges to a “Brownian process”
in distribution, it is enough to show EB∗t → 0 and for any 0< s < t < 1,
cov(B∗t ,B
∗
s )→ s,
cov(B∗t ,B
∗
s ) =
n
√
ts
[nt][ns]
cov(W2t,W2s)DVD
′
C
+ o(n−δ/3)
=
n
√
ts3/2
[nt][ns]
DVD′
C
+ o(n−δ/3)
=
n
√
ts3/2
[nt][ns]
D(nVar[θˆ(n)− θ] + o(1))D′
C
+ o(n−δ/3)
=
n2
√
ts3/2
[nt][ns]
∂h(θ1)/∂θ1Var[θˆ1(n)− θ1]∂h(θ1)/∂θ′1
C
+
n2
√
ts3/2
[nt][ns]
∂h(θ2)/∂θ2Var[θˆ2(n)− θ2]∂h(θ2)/∂θ′2
C
+ o(1)
=
n2
√
ts3/2
[nt][ns]
Var[h(θˆ1(n))] +Var[h(θˆ2(n))]
C
+ o(1)
=
n2ts2
[nt][ns]
+ o(1)
→ s a.s.
It is easy to see that EB∗t → 0. This completes the proof and shows that Bt
is asymptotical Brownian process in distribution.
Under H1, the sequential statistics
B∗t (θˆ([nt])) =
√
t
h(θˆ1([nt]))− h(θˆ2([nt]))− (h(θ1)− h(θ2))√
V̂ar(h(θˆ1([nt]))) + V̂ar(h(θˆ2([nt])))
+
√
t
h(θ1)− h(θ2)√
V̂ar(h(θˆ1([nt]))) + V̂ar(h(θˆ2([nt])))
.
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With similar proof, the first term converges to a standard Brownian motion
in distribution asymptotically. Because
[nt]V̂ar(h(θˆj([nt]))) = vj
(
N([nt])
[nt]
, θˆ([nt])
)
(1 + o(1)) a.s. j = 1,2,
we have that
√
t
h(θ1)− h(θ2)√
V̂ar(h(θˆ1([nt]))) + V̂ar(h(θˆ2([nt])))
converges to
t
√
n(h(θ1)− h(θ2))√
v1(ρ,θ) + v2(ρ,θ)
=
√
nµt(A.9)
in probability. Therefore, under H1, by Slutsky’s theorem, B
∗
t −
√
nµt con-
verges to a standard Brownian motion asymptotically. 
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